
Support for visibly fuller hair, backed by research
Minoxidil (2.5mg) can regrow lost hair and prolongs the growth (anagen) phase of hair follicles.
Thinning hair is common, but it doesn’t have to define your self-image. Eden’s Minoxidil tablets offer discreet, at-home support to help you maintain fuller-looking hair.
3 simple steps to a better you
Submit your application and meet with a doctor
Step 3
Complete a quick form and meet with a licensed medical provider 100% online. They’ll determine if a personalized treatment plan is right for you.

Get your medication delivered at home
Step 3
If eligible, your custom prescription will be shipped directly to your door, fast and free.

Receive 24/7 support and ongoing care
Step 3
We’ll be with you every step of the way, with regular check-ins and on-demand medical support to keep you on track.

More from our members
Individual results may vary. Testimonials reflect personal experiences and do not guarantee outcomes.

Renew your confidence. Embrace fuller hair. Feel youthful every day.
- 1-on-1 guidance from US-based health experts
- No-cost consultations for continuous treatment optimization
- Fast & reliable deliveries with 24/7 support available
Learn more about Minoxidil
Oral Minoxidil is FDA-approved for hypertension but is used off-label at low doses to support hair retention. It may influence scalp blood flow and the duration of the hair cycle.
No. Its use for hair support in women is off-label. However, it is commonly prescribed by specialists based on individual needs.
Doses typically range from 0.25 mg to 1.25 mg daily. Higher doses may increase risk of side effects without improving outcomes.
In studies, some participants noted improvements in hair shedding and appearance over 3–6 months, with additional changes over 6–12 months.
Low doses are generally well-tolerated. Side effects may include unwanted hair growth (face/body), dizziness, or fluid retention.
Yes. It is often paired with topical minoxidil or hormonal therapies like spironolactone under medical supervision.
No. Minoxidil is not recommended for use during pregnancy or lactation due to potential risks.
Hair thinning may gradually resume after stopping the medication.
Both can be effective. Oral forms may be preferred for those who find topicals irritating or inconvenient.
Only available if prescribed after an online consultation with a healthcare provider. Benefits outlined are based on third-party studies. Plans are offered as a subscription service which can be canceled at any time. Actual product packaging may appear differently than shown. Physicians may prescribe compounded medications as needed to meet patient requirements. The FDA does not review or approve any compounded medications for safety or effectiveness. The statements on this page have not been evaluated by the FDA. Results may vary. If you notice any side effects while using this treatment, contact your healthcare provider immediately.
Only available if prescribed after an online consultation with a healthcare provider. Benefits outlined are based on third-party studies. Plans are offered as a subscription service which can be canceled at any time. Actual product packaging may appear differently than shown. The statements on this page have not been evaluated by the FDA. Results may vary.
The statements on this page have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.
Important safety information- “All 159 Hair Loss Statistics of 2025 for Journalists.” Scandinavianbiolabs.Com, 24 Jan. 2025, scandinavianbiolabs.com/blogs/journal/hair-loss-statistics.
- Rodrigues-Barata R, et al., (2020). Low-dose oral minoxidil for female pattern hair loss: A unicenter descriptive study of 148 women. Skin Appendage Disord., 6(3):175–176.
- Vañó-Galván S, Pirmez R, Hermosa-Gelbard Á, et al. (2020). Safety of low-dose oral minoxidil in the treatment of hair disorders: A multicenter study of 1,404 patients. J Am Acad Dermatol, 84(6):1644–1651.
- Ramos PM, Miot HA. (2020). Female pattern hair loss: a clinical and pathophysiological review. An Bras Dermatol, 95(3):277–287.
- Perera E, et al. (2017). Treatment of chronic telogen effluvium with oral minoxidil: A retrospective study. F1000Res, doi: 10.12688/f1000research.11775.1.
- Pickart, Loren E., and Margot J. Margolina. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, vol. 19, no. 7, 2018, p. 1987. https://doi.org/10.3390/ijms19071987.
- "The Human Tripeptide GHK and Tissue Remodeling." Journal of Biomaterials Science, Polymer Edition, vol. 19, no. 8, 2008, pp. 969–988. https://doi.org/10.1163/156856208784909435
- Jiang F, Wu Y, Liu Z, Hong M, Huang Y. Synergy of GHK‐Cu and hyaluronic acid on collagen IV upregulation via fibroblast and ex‐vivo skin tests. Journal of Cosmetic Dermatology. 2023;22(9):2598-2604. Doi: https://doi.org/10.1111/jocd.15763







